Condition: Hepato Cellular Carcinoma (HCC) · Sponsor: University Hospital, Basel, Switzerland
IMPACT-TACE is an investigator-initiated, prospective, multicenter, randomized, double-blinded, interventional trial to test the hypothesis that the simultaneous application of doxorubicin with the ABCB1 inhibitor nicardipine would significantly improve the success rate of TACE treatment.
This description comes directly from the study's public registry record.
Fahim Ebrahimi, PD Dr. · +41 61 777 74 00 · fahim.ebrahimi@clarunis.ch
Always discuss trial participation with your own doctor first.
| University Hospital Basel | Basel, Switzerland | Recruiting |
| Hôpitaux Universitaires de Genève | Geneva, Switzerland | Recruiting |
| Kantonsspital St. Gallen | Sankt Gallen, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07302919